RECRUITING

Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a single site nonrandomized pilot clinical trial of the feasibility, acceptability, and efficacy of a combination treatment involving digital Cogmed working memory skills training, social support components, and memory strategy training to improve adherence to Cogmed in youth with sickle cell disease ages 7-16 years.

Official Title

Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell (ALL IN)

Quick Facts

Study Start:2025-01
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06770010

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:7 Years to 16 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. 1. Diagnosis of sickle cell disease (any genotype).
  2. 2. Between ages 7-16 years old.
  3. 3. Patients will only enter the treatment phase if they score \>1 SD below the normative mean on at least one standardized working memory assessment (i.e., Digit Span or Spatial Span subtests) or demonstrate a relative weakness in working memory (\>1 SD below the estimated IQ).
  1. 1. Motor, visual, or auditory impairment that prevents computer use.
  2. 2. Diagnosis of a mental health condition that precludes, or takes treatment precedence over, participation in the cognitive training.
  3. 3. History of photosensitive seizures.
  4. 4. Insufficient English fluency.
  5. 5. Recent initiation or dose adjustment of a stimulant medication to treat attention problems (\< 30 days).

Contacts and Locations

Study Contact

Steven Hardy, PhD
CONTACT
202-476-5000
sjhardy@childrensnational.org
Sara Ropeta, BS
CONTACT
202-476-5000
sropeta@childrensnational.org

Principal Investigator

Steven Hardy, PhD
PRINCIPAL_INVESTIGATOR
Children's National Research Institute

Study Locations (Sites)

Children's National Hospital
Washington, District of Columbia, 20010
United States

Collaborators and Investigators

Sponsor: Children's National Research Institute

  • Steven Hardy, PhD, PRINCIPAL_INVESTIGATOR, Children's National Research Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01
Study Completion Date2026-12

Study Record Updates

Study Start Date2025-01
Study Completion Date2026-12

Terms related to this study

Additional Relevant MeSH Terms

  • Sickle Cell Disease